|
業務類別
|
-- |
|
業務概覽
|
Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2024, 41.8% of the firm's total revenue comes from its innovative product category, which includes innovative drugs and biosimilar drugs. Sino Biopharm's biggest revenue segment is oncology medicines, accounting for 37.2% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas. |
| 公司地址
| 1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Hong Kong, HKG |
| 電話號碼
| +852 28029886 |
| 傳真號碼
| +852 28800847 |
| 公司網頁
| https://www.sbpgroup.com |
| 員工數量
| 21435 |
| Mr. Eric S Y Tse |
Director and Chief Executive Officer |
-- |
29/04/2025 |
| Ms. Cheung Ling Cheng |
Executive Vice Chairman of the Board |
-- |
29/04/2025 |
| Mr. Hsin Tse |
Director and Senior Vice President |
-- |
29/04/2025 |
| Dr. Ping Tse |
Senior Vice Chairman of the Board |
-- |
29/04/2025 |
|
|
| Dr. Kwok Tung Donald Li, J.P. |
Independent Director |
29/04/2025 |
| Mr. Lu Fu Zhang |
Independent Director |
29/04/2025 |
| Ms. Hong Lu |
Independent Director |
29/04/2025 |
| Mr. Eric S Y Tse |
Director and Chief Executive Officer |
29/04/2025 |
| Ms. Cheung Ling Cheng |
Executive Vice Chairman of the Board |
29/04/2025 |
| Mr. Dakui Li |
Independent Director |
29/04/2025 |
| Mr. Zhoushan Tian |
Director |
29/04/2025 |
| Mr. Hsin Tse |
Director and Senior Vice President |
29/04/2025 |
| Ms. Theresa Y Y Tse |
Executive Chairwoman of the Board |
29/04/2025 |
| Dr. Ping Tse |
Senior Vice Chairman of the Board |
29/04/2025 |
| Mr. Zhengfei Lu |
Independent Director |
29/04/2025 |
|
|
|
|
